Artera Webmd Artera Together, webmd provider services and artera improve access and engagement to patient education materials and medication affordability programs. a partnership for you and your patients. Paul nguyen discusses the artera ai prostate test for post prostatectomy bcr. the test combines clinical factors with ai analyzed digital pathology from prostatectomy specimens.
Artera Webmd Artera Artera has secured ce marking under the eu ivdr for its arteraai prostate biopsy and breast cancer assays, expanding the company’s global reach. Together, artera and webmd help providers improve clinical outcomes by providing patients with a simple, seamless access point for information while reducing friction points in the patient journey. Dual regulatory milestones establish artera as a global ai leader in precision oncology san francisco, april 21, 2026— artera, a developer of multimodal ai based prognostic and predictive cancer tests, announced today that it was granted ce marking under the european union in vitro diagnostic regulation (eu ivdr) for both its arteraai prostate biopsy assay and arteraai breast cancer assay. New york — artera, a developer of artificial intelligence based cancer tests, said on tuesday that it has received ce marking for its prostate cancer and breast cancer assays. the arteraai prostate biopsy assay and arteraai breast cancer assay use ai powered algorithms to analyze digital histopathology images, along with patient clinical data, to determine cancer aggressiveness and help.
Webmd Strikes Deal With Patient Communications Platform Artera Dual regulatory milestones establish artera as a global ai leader in precision oncology san francisco, april 21, 2026— artera, a developer of multimodal ai based prognostic and predictive cancer tests, announced today that it was granted ce marking under the european union in vitro diagnostic regulation (eu ivdr) for both its arteraai prostate biopsy assay and arteraai breast cancer assay. New york — artera, a developer of artificial intelligence based cancer tests, said on tuesday that it has received ce marking for its prostate cancer and breast cancer assays. the arteraai prostate biopsy assay and arteraai breast cancer assay use ai powered algorithms to analyze digital histopathology images, along with patient clinical data, to determine cancer aggressiveness and help. New york– (business wire)– webmd provider services today announced a partnership with saas patient communications leader artera™ (formerly well health) to improve access and engagement to patient education materials and medication affordability programs. Artera has secured ce marking under the european union in vitro diagnostic regulation (eu ivdr) for its arteraai prostate biopsy and breast cancer assays, expanding the company’s global reach. Webmd provider services has announced a partnership with saas patient communications leader artera (formerly well health) to improve access and engagement to patient education materials and medication affordability programs. Artera secures ce marking for its ai prostate and breast cancer assays, unlocking global expansion artera, a developer of multimodal ai based prognostic and predictive cancer tests, announced today that it was granted ce marking under the european union in vitro diagnostic regulation (eu ivdr) for both its arteraai prostate biopsy assay and arteraai breast cancer assay, marking a major step in.
Comments are closed.